UBS Affirms Neutral Rating on Baxter International (BAX)
Baxter International Inc. (NYSE:BAX) is one of the 12 best healthcare stocks to buy now. On June 11, UBS reiterated a ‘Neutral’ rating on the stock and a $35 price target.
Baxter International Inc (BAX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Pzena Investment Management Richard S. Pzena | 36,772,566 | $1,258,724,934 | +10% | 4.39% |
| 2. | Harris Associates Natixis Global Asset Management | 9,003,931 | $308,204,566 | +7% | 0.52% |
| 3. | Camber Capital Management Stephen Dubois | 5,750,000 | $196,822,500 | +25% | 6.99% |
| 4. | 2,000,000 | $68,460,000 | 3.37% | ||
| 5. | Deerfield Management James E. Flynn | 1,923,100 | $65,827,713 | 1.3% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $82.19 | 9,780 | $803,818.20 | 39,504 | 2020-03-30 | Filing | |
| $42.75 | 11,691 | $499,790.25 | 11,691 | 2016-05-23 | Filing | |
| $72.38 | 50 | $3,619.00 | 696 | 2014-04-24 | Filing | |
| $68.00 | 55 | $3,740.00 | 646 | 2014-03-25 | Filing | |
| $67.39 | 81 | $5,458.59 | 591 | 2014-03-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.61 | 64,488 | $2,618,857.68 | 142,290 | 2024-03-01 | Filing | |
| $37.52 | 3,930 | $147,453.60 | 36,835 | 2023-03-20 | Filing | |
| $40.50 | 3,813 | $154,426.50 | 16,725 | 2023-02-21 | Filing | |
| $44.70 | 59,477 | $2,658,621.90 | 126,231 | 2023-01-17 | Filing | |
| $76.63 | 1,215 | $93,105.45 | 34,127 | 2022-04-05 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 603,876 | $18,351,792 | 1.31% | |
| 2. | 219,512 | $6,646,823 | 0.22% | |
| 3. | 15,000 | $454,200 | 0.06% | |
| 4. | 3,324 | $100,654 | 0.02% | |
| 5. | 156 | $4,714 | 0% |
News See All
12 Best Healthcare Stocks to Buy Now
Healthcare companies in the US are facing policy headwinds under President Donald Trump's Administration.
Baxter International (BAX) Rebounded in Q1 After Reporting Strong Earnings
Artisan Partners, an investment management company, released its “Artisan Mid Cap Value Fund” first-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Baxter International (BAX) Traded Higher Despite Tariff Disruptions
Broyhill Asset Management, an investment advisor, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Baxter International Inc. (NYSE:BAX) Q1 2025 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to Baxter International's First Quarter 2025 Earnings Conference Call.
8 Most Undervalued Healthcare Stocks to Buy According to Analysts
Healthcare prices and expenditures have been rising in the United States.
Here’s Why Baxter International (BAX) Fell in Q4
Artisan Partners, an investment management company, released its “Artisan Mid Cap Value Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here.
Baxter International Inc. (NYSE:BAX) Q4 2024 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to Baxter International's Fourth Quarter 2024 Earnings Conference Call.
10 Biggest Dividend Cuts and Suspensions of 2024
Dividends hold great appeal for investors—they appreciate receiving them and strongly dislike reductions.
Should You Hold Baxter International (BAX) for the Long Term?
Broyhill Asset Management, an investment advisor, released a third-quarter 2024, investor letter. A copy of the letter can be downloaded here.
Billionaire Hedge Funds
